KIYATEC offers predictive, in-vitro, 3D primary tumor screens
KIYATEC prioritizes accurate ex-vivo prediction of patients’ drug response, focused primarily on data correlation to human clinical outcomes. Our drug response profiling services utilize phenotypic 3D cell-based models and primary patient tumors for predicting both chemotherapeutic and targeted agent drug response. KIYATEC’s 3D perfusion tissue microenvironments are particularly useful for investigating drug efficacy and modeling resistance of cancer therapeutics.
SEE US AT AACR BOOTH 2365